- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Instrumentarium, Nycomed join online exchange
Instrumentarium Imaging and Nycomed Amersham are the latest medical device companies to promote themselves through e-business. Instrumentarium announced this month that it intends to join the Global Healthcare Exchange, a consortium of medical
Instrumentarium Imaging and Nycomed Amersham are the latest medical device companies to promote themselves through e-business. Instrumentarium announced this month that it intends to join the Global Healthcare Exchange, a consortium of medical device companies, while Nycomeds announcement came just last week.
Abbott Laboratories, Baxter International, GE Medical Systems, Johnson & Johnson, and Medtronic founded the exchange this past spring (SCAN 4/14/00). The site will provide access to product catalogues and online ordering and status confirmation. The exchange is expected to launch this fall in the U.S. and to expand worldwide.
The five companies, plus Instrumentarium, Nycomed, and other companies that have since joined, are equal partners in ownership of the healthcare exchange. The exchange is set to launch at the end of September, when it will announce its final name.
Nycomed specializes in imaging agents and oncology therapies. Instrumentarium of Finland specializes in anesthesia and other medical equipment.
The online exchange will offer medical devices, imaging products, and accessories from a variety of manufacturers. Exchange creators say customers will probably be hospitals and acute-care clinics. They will be able to simultaneously order equipment and get clinical information about products.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
